Anavex Life Sciences Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVXL research report →
About the company
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome.
- CEO
- Christopher U. Missling
- IPO
- 2006
- Employees
- 42
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $255.77M
- P/E
- -6.15
- P/S
- 0.00
- P/B
- 1.94
- EV/EBITDA
- -3.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.76%
- ROIC
- -35.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-46,377,000 · -7.85%
- EPS
- $-0.54 · -3.85%
- Op Income
- $-51,408,000
- FCF YoY
- -26.72%
- 52W High
- $13.99
- 52W Low
- $2.41
- 50D MA
- $2.88
- 200D MA
- $4.70
- Beta
- 1.12
- Avg Volume
- 1.21M
Get TickerSpark's AI analysis on AVXL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Kellmeyer Terrie | other | 46,668 |
| May 4, 26 | Kellmeyer Terrie | other | 7,500 |
| May 4, 26 | Kellmeyer Terrie | other | 50,000 |
| Feb 23, 26 | Paeger Axel | other | 0 |
| Jan 6, 26 | MISSLING CHRISTOPHER U | other | 125,000 |
| Jan 6, 26 | Boenisch Sandra | other | 12,500 |
| Oct 2, 25 | Boenisch Sandra | other | 12,500 |
| Oct 2, 25 | MISSLING CHRISTOPHER U | other | 125,000 |
| Sep 11, 25 | MISSLING CHRISTOPHER U | other | 187,500 |
| Sep 11, 25 | MISSLING CHRISTOPHER U | other | 145,048 |
Our AVXL coverage
Recent articles, reports, and earnings notes.
No research on AVXL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVXL report →Similar companies
Peers in the same neighborhood.